[Ip-health] EC claims 'FTA no harm A2M', Cameroon demonstrations

Khalil Elouardighi gerrold at noos.fr
Fri Feb 17 03:12:33 PST 2012

Dear all,

After a demonstration by Cameroonian AIDS activists last week (1), the
European Commission put out on its website a statement (2) denying the
existence of anti-generics provisions in the Free Trade Agreement with
India, and promising that no harm will come to access to medicines as a
result of the FTA (3).

It seems that the EC's strategy is to use of the secrecy shrouding the FTA
negotiations in order to simply deny what they're inserting in it.

Is anyone with access to information about the FTA's content able to debunk
or disprove the EC's claims that there are no provisions harmful to access
to medicines in the FTA ?


(1) See the Cameroon AIDS activists' demonstration at the EC embassy in
Yaoundé, Cameroon's capital :

(2) See the EC's harm-denying statement on its website :
0120215_fr.htm . 

(3) French-to-English translation of the EC's statement :

1 - The provisions in the Intellectual Property chapter of the Free Trade
Agreement that the EU is negotiating with India do not undermine in any way
India's right to manufacture and export generic drugs to other developing
countries. Moreover, the EU has proposed inserting a clause to ensure that
nothing in the agreement would limit the right of either party to produce
and export essential medicines.

2 - There are no plans to introduce provisions that would require India to
take additional measures to protect pharmaceutical research data, much less
extend the term of exclusive protection of patents beyond what is already
required by the TRIPS Agreement.

Therefore, the Delegation of the European Union in Cameroon wants to
reassure the Cameroonian public that the free trade agreement negotiated
between the EU and India will not compromise access to essential medicines
in developing countries.

The European Union was among the chief promoters of the Doha Declaration on
TRIPS and Public Health, which allowed countries that are not able to
manufacture pharmaceuticals to procure cheaper copies elsewhere where
necessary. The European Union fully supports and consistently applies the
TRIPS flexibilities.

More information about the Ip-health mailing list